Clinical Trial Update: A Safety and Tolerability Study of FCN-207 in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of FCN-207 in healthy volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperuricemia

Drugs mentioned

• FCN-207

Snippet

Sponsor: Fochon Pharmaceuticals, Ltd. | Conditions: Hyperuricemia | Phase 1 | Status: COMPLETED